![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Triple Antiviral Combo Shows Promise in COVID-19 Trial
Triple Antiviral Combo Shows Promise in COVID-19 Trial
![Triple Vaccine, needles](https://www.fdanews.com/ext/resources/test/Drug-Images4/triple-combination-vaccine-three-needles.gif?t=1589233681&width=430)
A triple antiviral combination has shown promise in a phase 2 trial of 127 patients in Hong Kong with mild to moderate COVID-19.
The researchers tested a combination of the HIV antiviral lopinavir-ritonavir, the hepatitis C treatment ribavirin and the multiple sclerosis treatment interferon beta-1, and found that the combination suppressed the virus at day seven, five days earlier than in participants given lopinavir-ritonavir alone.
The triple combination was also shown to be safe, with only minor gastrointestinal adverse events, including diarrhea and vomiting.
Upcoming Events
-
21Oct